TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Apolipoprotein B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of Life scale changes
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HbA1c at 3 months for participants with HbA1c ≥ 7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c at 6 months for participants with HbA1c ≥ 7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c at 6 months for participants with HbA1c < 7.5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pendulum Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid use in milligram morphine equivalents (MME)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Opioid initiation in the opioid-naive
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects free of safety events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects meeting pre-specified events - Cohort 1
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects meeting pre-specified events - Cohort 2
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage change in problem behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of UTI in CKD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Clinically significant abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Quantify nerve fibers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Identifying neural markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daily calorie intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Responsive Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One-leg standing test (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed 25-foot walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stride length (mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain by Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change on positive mental health scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Event free survival (EFS) rate
Endpoint domain: Mortality/survival
Primary endpoint: Preschool Word and Print Awareness (PWPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phonological Awareness Literacy Screening (PALS): Alphabet Knowledge and Name Writing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Woodcock Johnson Test of Achievement- IV (WJ-IV): Word Attack and Letter-Word Identification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Woodcock Johnson Test of Achievement- IV (WJ-IV): Spelling, Passage Comprehension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EBOV-specific IgG levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cotinine-confirmed 30-day point prevalence abstinence from all nicotine and tobacco
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total plasma essential amino acids (EAA) area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma EAA time-to-peak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma EAA C(MAX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Numeric Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Cardiovascular event at One year follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Success rate of 16-hour wear-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom collection success rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Average non-invasive tear film break-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient uptake of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient acceptance of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in volume of observed urine leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rates of change in revised ALS functional rating scale (ALSFRS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of change in Slow vital capacity (SVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of change in Spastic paraplegia rating scale (SPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mass balance of TNP-2092 and the percentages of radiolabel recovered in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics (PK) of TNP-2092 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of IGLON5 disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Visceral-to-subcutaneous fat area ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline assessment of knowledge level on HPV Infection and Vaccination
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline score of HPV Infection and Vaccination Health Belief Model Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Decrease of Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase Soft tissue healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Trismus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of Swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity measures change: time and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sedentary behaviour measures change: time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive functions measures change
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Distance achieved in incremental shuttle walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval-cancer rate
Endpoint domain: Adverse events/effects
Primary endpoint: Absence of SRF and IRF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an AE/ADR
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with a SAE/SADR
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with an UAE/UADR
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with a SUAE/SUADR
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax after first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax after multiple doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global cognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: C-terminal peptide of type 1 collagen (CTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinically important changes from baseline after ZVS101e treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed up and go with 25 steps walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief International Cognitive Assessment for MS (BICAMS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Effectiveness against insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Intelligibility of recorded speech
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain, Enjoyment, and General Activity Scale (PEG-3)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Average Change from Baseline in MG-ADL Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Global health status score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PTH in blood serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse Event of Special Interests
Endpoint domain: Adverse events/effects
Primary endpoint: Reversal from TOFc 3 to TOFr 1.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal from TOFc 3 to TOFr 0.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of PRBCs transfused per VA-ECMO day of support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scale of Balance Recovery Confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Falls Efficacy Scale - International
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Late-Life Function and Disability Instrument-Function component
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area-Under-the-Curve (AUC) of Pravastatin After Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Pravastatin After Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area-Under-the-Curve (AUC) of Chenodeoxycholic Acid After Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Chenodeoxycholic Acid After Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: inhibition of biofilm formation of c.acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: improvement of antibiotic sensitivity of c.acne
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disease specific primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular distance-corrected visual acuity at distance (6m)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Binocular distance-corrected visual acuity at intermediate (66cm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intervention recruitment rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: intervention retention rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: treatment acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in participant's blood pressure control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in participant's glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Patient Assessment of Chronic Illness Care scale (PACIC)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: bioavailability of ethinyl estradiol/etonogestrel vaginal ring formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of decrease of high sensitive cardiac troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fear of re-injury
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Absence of reinduction of AVNRT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Hypertrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stimulant Use
Endpoint domain: Adverse events/effects
Primary endpoint: The Neck Disability Index (NDI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Covid-19 Vaccine Uptake
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Normal brain 18F-FDG PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dichotomised diabetes risk status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression-free survival time (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Pathologic outcome on surveillance prostate biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of participants who go onto whole gland salvage treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Salvage whole gland treatment free survival
Endpoint domain: Mortality/survival
Primary endpoint: bispectral index (BIS) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversal of iron deficient anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pleasant drug effect
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: functional outcome of activity of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: functional outcome of cardiovascular and respiratory system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: functional outcome for assessing dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: functional outcome of mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: functional outcome of lower limbs strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: functional outcome of static balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: endoscopists accuracy in optical diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of participants achieving NASH resolution without worsening of fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean change in ocular redness at 15 minutes post-instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in ocular redness at 10 hours post-instillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Serum Potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients discussed in multidisciplinary team
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Healthcare resource utilization of different therapeutic approaches
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Direct medical costs of different therapeutic approaches
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change of spontaneous utterances (SCU)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 2-year recurrence rate of Dupuytren's disease
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Leeds Dyspepsia Questionnaire (LDQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LC-MS/MS assay-specific cut-off point for screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: LC-MS/MS assay-specific cut-off point for CCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: The six-minute walking test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Maternal Perceived Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Amoxicillin Level in Plasma during Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amoxicillin Level in Cord Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Amoxicillin Level in Plasma in the Postpartum state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft tissue to bone healing in the shoulder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Self-care agency scale score level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Coping orientation to problems experienced (COPE)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient general satisfaction with full dentures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum SUV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUV Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target-to-Background Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Influx (Ki)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution volume (Vt) for scan times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Capacity to consent
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sunnybrook Facial Grading System
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cyst wall destruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Average weekly steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weekly participation in mild, moderate, and vigorous exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily engagement in sedentary behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically Meaningful Findings in Columbia Suicide Severity Rating Scale (C-SSRS) Responses
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with new HIV infection
Endpoint domain: Mortality/survival
Primary endpoint: Client Satisfaction Scale (CSQ) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Isavuconazole clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Isavuconazole volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Coenzyme Q10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total antioxidants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in disease impact questionnaire WPI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Traumatic intracranial lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total and regional body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emergent Adverse Events assessed by physical and neurological examination
Endpoint domain: Adverse events/effects
Primary endpoint: Emergent Adverse Events assessed by evaluation of the results of the analysis with hematology and biochemistry
Endpoint domain: Adverse events/effects
Primary endpoint: Emergent Adverse Events assessed by brain RM image
Endpoint domain: Adverse events/effects
Primary endpoint: Emergent Adverse Events assessed by AC_PET with 18-FdG
Endpoint domain: Adverse events/effects
Primary endpoint: ECG detection efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: physician understanding of diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: physician perception of participant understanding
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: participant understanding of diagnosis and treatment plan
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: understanding of diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: decision making
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Plasma Concentration of Ravulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Free C5 Concentration of Ravulizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative 28-day Pediatric Logistic Organ Dysfunction (PELOD-2) score
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of hospital-acquired infections
Endpoint domain: Adverse events/effects
Primary endpoint: Slope of left ventricular mass index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes